A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LPM6690176 Capsules in Patients With Advanced Solid Tumors
Latest Information Update: 20 Mar 2024
At a glance
- Drugs LPM 6690176 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Luye Pharma Group
Most Recent Events
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 14 Feb 2024 New trial record